Preparation and Prosecution Sample Clauses
Preparation and Prosecution. The Parties will respectively prepare, file, maintain and Prosecute the Takeda Patent Rights, Licensee Patent Rights, and Joint Patent Rights as set forth in this Section 10.4 (Prosecution of Patent Rights). Each Party will designate a primary contact for issues related to Prosecution of Patent Rights as set forth under this Agreement. The primary contact for each Party will work with the primary contact for the other Party to ensure a coordinated strategy for Prosecution of such Patent Rights. The Parties shall discuss in good faith appointment of a single outside counsel for Prosecution of both the Takeda Patent Rights and the Licensee Patent Rights that Cover the TAK-385 Licensed Compound or any TAK-385 Licensed Product. Licensee shall have the right to select such outside counsel, subject to Takada’s consent, such consent not to be unreasonably withheld, conditioned, or delayed.
Preparation and Prosecution. Each party will prepare and determine the content of its own regulatory filings, be responsible for the cost of such filings, including FDA user fees, and control the prosecution of its own regulatory submissions; provided that, Medtronic shall be entitled to give Orphan appropriate input and advice regarding those portions of Orphan's regulatory filings which relate to the System and Orphan shall be entitled to give Medtronic appropriate input and advice regarding those portions of Medtronic's regulatory filings which relate to the Drug. Reasonable effort will be made to have Medtronic and Orphan co-participate in discussions with the FDA involving Drug-System Combination aspects of clinical trial design, interaction between the Drug and System, or Mechanical Delivery of the Drug. Neither party will discuss the other party's product with the FDA without the other party present. *** DENOTES CONFIDENTIAL INFORMATION THAT HAS BEEN OMITTED FROM THE EXHIBIT AND FILED SEPARATELY, ACCOMPANIED BY A CONFIDENTIAL TREATMENT REQUEST, WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. Upon request, each party agrees to support the other party, as may be reasonably necessary to expeditiously advance the Collaborative Activities, in any discussions with the FDA or Clinical Investigators directly related to the Drug-System Combination or Joint Clinical Trials. Discussions with the FDA with respect to the Drug alone or the System alone will be handled solely by the responsible party, unless such responsible party requests the support of the other party.
Preparation and Prosecution. Commencing upon the Effective Date, AGTC shall assume control of all patent prosecution and maintenance of the Patent Rights, provided, however, AGTC will keep Icagen reasonably advised as to the prosecution status of all Patent Rights by directing patent counsel to forward to Icagen copies of all official communications from or to the PTO or other governmental or patent office regarding the Patent Rights. Icagen shall have the right to review all official correspondence and filings made by or on behalf of AGTC with respect to such Patent Rights, including without limitation, Office Action responses, prior to submission and AGTC agrees to reasonably consider Icagen’s timely input with respect thereto. All information regarding the filing, prosecution and maintenance of the Patent Rights disclosed by AGTC to Icagen shall constitute AGTC’s Confidential Information, and shall not be used by Icagen other than for the research, development, manufacture and commercialization of compounds or products in accordance with the license granted to Icagen in Section 3.1 or as otherwise permitted pursuant to Article 8.